
About
LIDE Biotech is an oncology-focused preclinical CRO serving drug developers and research partners. It operates China-based labs with US and Europe-based leadership to support preclinical oncology, immuno-oncology, and related translational studies.
Services
Preclinical oncology studies
Runs preclinical studies for oncology drug R&D across in-vivo and in-vitro model systems.
Immuno-oncology platform
Provides syngeneic, humanized, IO-FIVE, and co-culture models and assays for immunotherapy development.
Drug resistant cancer models
Offers patient-derived models and studies focused on drug-resistant cancers.
ADC development support
Supports antibody-drug conjugate development with preclinical models and assays.
Patient-derived xenograft (PDX) models
Provides a large library of patient-derived xenograft models for model search and study use.
Cell line-derived xenograft (CDX) models
Provides ready-to-use CDX models for early in-vivo screening.
Orthotopic models
Builds orthotopic models from PDX or CDX tissue for solid and liquid cancers.
Syngeneic models
Offers immunocompetent murine tumor models for proof-of-concept and mechanism-of-action studies.
12 more services
- Humanized models
- Ex vivo models
- 3D spheroid and organoid assays
- CR cells
- Co-culture assays for IO
- Multi-omics analysis
- Transcription analysis and bioinformatics
- Sequencing
- Functional genomic imaging (FGI)
- Multiplex tissue imaging
- Academic collaborations
- Buying models
- Turnaround
- 7-10 days
- As little as 14 days
- What to send
- Work email
- Study needs
- Near-term deadlines
Capabilities
- Assays and studies
- ADCs
- Antibodies
- Cell therapy
- In-vivo efficacy studies
- Mechanism-of-action studies
- Proof-of-concept studies
5 more
- Functional immune profiling
- Biomarker discovery
- High-throughput pre-validation
- Compound screens
- Efficacy studies
- Scale and capacity
- 2300+ PDX models
- 120 CDX models
- 225 frozen PDXO models across 21 cancer types
- Therapeutic areas
- Oncology
- Immuno-oncology
- Hematological malignancies
- Blood cancers
- Drug-resistant cancers
Instruments and platforms
- MiniPDX
- IO-FIVE
- OncoVee™ K-Cell 1000 Cell Kit
- Functional genomic imaging (FGI)
Modalities and species
- Modalities
- Antibody
- Bispecific
- ADC
- Cell therapy
- Species and models
- Murine tumor models
- huPBMC-reconstituted humanized models
- CD34+ HSC humanized models
- Humanized syngeneic models
- Innate immune cell–involved systems
- Macrophage
9 more
- Dendritic cell
- Patient-derived xenografts
- Cell line-derived xenografts
- Organoids
- 3D spheroids
- CR cells
- PBMC humanized models
- T/NK
- CAR-T
Certifications
As the company states them, with the certificate or registry record where there is one.
AAALACSelf-reported
Scope: labs
CAPSelf-reported
Details
- Type
- CRO
- Founded
- 2011
- Sites
- Shanghai, China
- San Francisco, USA
- Philadelphia, USA
- Nottingham, UK
- Serves
- Global, North America, Europe, APAC